Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

Frank Kroschinsky; Jan Moritz Middeke; Martin Janz; Georg Lenz; Mathias Witzens-Harig; Reda Bouabdallah; Paul La Rosée; Andreas Viardot; Gilles Salles; Seok Jin Kim; Tae Min Kim; Oliver Ottmann; Joerg Chromik; Anne Marie Quinson; Ute von Wangenheim; Ute Burkard; Andreas Berk; Norbert Schmitz

doi:10.1007/s10637-020-00949-8

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, Georg Lenz, Mathias Witzens-Harig, Reda Bouabdallah, Paul La Rosée, Andreas Viardot, Gilles Salles, Seok Jin Kim, Tae Min Kim, Oliver Ottmann, Joerg Chromik, Anne Marie Quinson, Ute von Wangenheim, Ute Burkard, Andreas Berk, Norbert Schmitz

Research output: Contribution to journal › Comment/debate

Abstract

The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Original language	English
Pages (from-to)	283-284
Number of pages	2
Journal	Investigational New Drugs
Volume	39
Issue number	1
DOIs	https://doi.org/10.1007/s10637-020-00949-8
State	Published - Feb 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-020-00949-8

Fingerprint

Dive into the research topics of 'Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)'. Together they form a unique fingerprint.

Cite this

Kroschinsky, F., Middeke, J. M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S. J., Kim, T. M., Ottmann, O., Chromik, J., Quinson, A. M., von Wangenheim, U., Burkard, U., Berk, A., & Schmitz, N. (2021). Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3). Investigational New Drugs, 39(1), 283-284. https://doi.org/10.1007/s10637-020-00949-8

@article{7d8cd2881ad948f6ae9400d049733c46,

title = "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)",

abstract = "The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.",

author = "Frank Kroschinsky and Middeke, \{Jan Moritz\} and Martin Janz and Georg Lenz and Mathias Witzens-Harig and Reda Bouabdallah and \{La Ros{\'e}e\}, Paul and Andreas Viardot and Gilles Salles and Kim, \{Seok Jin\} and Kim, \{Tae Min\} and Oliver Ottmann and Joerg Chromik and Quinson, \{Anne Marie\} and \{von Wangenheim\}, Ute and Ute Burkard and Andreas Berk and Norbert Schmitz",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = feb,

doi = "10.1007/s10637-020-00949-8",

language = "English",

volume = "39",

pages = "283--284",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

Kroschinsky, F, Middeke, JM, Janz, M, Lenz, G, Witzens-Harig, M, Bouabdallah, R, La Rosée, P, Viardot, A, Salles, G, Kim, SJ, Kim, TM, Ottmann, O, Chromik, J, Quinson, AM, von Wangenheim, U, Burkard, U, Berk, A & Schmitz, N 2021, 'Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)', Investigational New Drugs, vol. 39, no. 1, pp. 283-284. https://doi.org/10.1007/s10637-020-00949-8

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3). / Kroschinsky, Frank; Middeke, Jan Moritz; Janz, Martin et al.
In: Investigational New Drugs, Vol. 39, No. 1, 02.2021, p. 283-284.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

AU - Kroschinsky, Frank

AU - Middeke, Jan Moritz

AU - Janz, Martin

AU - Lenz, Georg

AU - Witzens-Harig, Mathias

AU - Bouabdallah, Reda

AU - La Rosée, Paul

AU - Viardot, Andreas

AU - Salles, Gilles

AU - Kim, Seok Jin

AU - Kim, Tae Min

AU - Ottmann, Oliver

AU - Chromik, Joerg

AU - Quinson, Anne Marie

AU - von Wangenheim, Ute

AU - Burkard, Ute

AU - Berk, Andreas

AU - Schmitz, Norbert

PY - 2021/2

Y1 - 2021/2

N2 - The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

AB - The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

UR - https://www.scopus.com/pages/publications/85086784183

U2 - 10.1007/s10637-020-00949-8

DO - 10.1007/s10637-020-00949-8

M3 - Comment/debate

C2 - 32474843

AN - SCOPUS:85086784183

SN - 0167-6997

VL - 39

SP - 283

EP - 284

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R et al. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3). Investigational New Drugs. 2021 Feb;39(1):283-284. doi: 10.1007/s10637-020-00949-8

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this